Literature DB >> 27058680

Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system.

Shannon M Smith1, Dagmar Amtmann, Robert L Askew, Jennifer S Gewandter, Matthew Hunsinger, Mark P Jensen, Michael P McDermott, Kushang V Patel, Mark Williams, Elizabeth D Bacci, Laurie B Burke, Christine T Chambers, Stephen A Cooper, Penney Cowan, Paul Desjardins, Mila Etropolski, John T Farrar, Ian Gilron, I-zu Huang, Mitchell Katz, Robert D Kerns, Ernest A Kopecky, Bob A Rappaport, Malca Resnick, Vibeke Strand, Geertrui F Vanhove, Christin Veasley, Mark Versavel, Ajay D Wasan, Dennis C Turk, Robert H Dworkin.   

Abstract

Clinical trial participants often require additional instruction to prevent idiosyncratic interpretations regarding completion of patient-reported outcomes. The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership developed a training system with specific, standardized guidance regarding daily average pain intensity ratings. A 3-week exploratory study among participants with low-back pain, osteoarthritis of the knee or hip, and painful diabetic peripheral neuropathy was conducted, randomly assigning participants to 1 of 3 groups: training with human pain assessment (T+); training with automated pain assessment (T); or no training with automated pain assessment (C). Although most measures of validity and reliability did not reveal significant differences between groups, some benefit was observed in discriminant validity, amount of missing data, and ranking order of least, worst, and average pain intensity ratings for participants in Group T+ compared with the other groups. Prediction of greater reliability in average pain intensity ratings in Group T+ compared with the other groups was not supported, which might indicate that training produces ratings that reflect the reality of temporal pain fluctuations. Results of this novel study suggest the need to test the training system in a prospective analgesic treatment trial.

Entities:  

Mesh:

Year:  2016        PMID: 27058680     DOI: 10.1097/j.pain.0000000000000502

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  26 in total

Review 1.  Reporting of Design Features and Analysis Details in Randomized Clinical Trials of Procedural Treatments for Cancer Pain: An ACTTION Systematic Review.

Authors:  Daniel Rothstein; Rachel A Kitt; Shannon M Smith; Salahadin Abdi; Mitchell P Engle; Michael P McDermott; Srinivasa N Raja; Dennis C Turk; Robert H Dworkin; Jennifer S Gewandter
Journal:  Reg Anesth Pain Med       Date:  2017 May/Jun       Impact factor: 6.288

Review 2.  Breaking barriers to novel analgesic drug development.

Authors:  Ajay S Yekkirala; David P Roberson; Bruce P Bean; Clifford J Woolf
Journal:  Nat Rev Drug Discov       Date:  2017-06-09       Impact factor: 84.694

3.  [What does pain intensity mean from the patient perspective? : A qualitative study on the patient perspective of pain intensity as an outcome parameter in treatment evaluation and on the interpretability of pain intensity measurements].

Authors:  K Neustadt; S Deckert; C Kopkow; A Preißler; B Bosse; C Funke; L Jacobi; P Mattenklodt; B Nagel; P Seidel; R Sittl; E Steffen; R Sabatowski; J Schmitt; U Kaiser
Journal:  Schmerz       Date:  2017-12       Impact factor: 1.107

Review 4.  Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

Authors:  Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; Eric G Devine; David Hewitt; Mark P Jensen; Nathaniel P Katz; Amy A Kirkwood; Richard Malamut; John D Markman; Bernard Vrijens; Laurie Burke; James N Campbell; Daniel B Carr; Philip G Conaghan; Penney Cowan; Mittie K Doyle; Robert R Edwards; Scott R Evans; John T Farrar; Roy Freeman; Ian Gilron; Dean Juge; Robert D Kerns; Ernest A Kopecky; Michael P McDermott; Gwendolyn Niebler; Kushang V Patel; Richard Rauck; Andrew S C Rice; Michael Rowbotham; Nelson E Sessler; Lee S Simon; Neil Singla; Vladimir Skljarevski; Tina Tockarshewsky; Geertrui F Vanhove; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2019-12-13       Impact factor: 5.820

Review 5.  Composite Pain Biomarker Signatures for Objective Assessment and Effective Treatment.

Authors:  Irene Tracey; Clifford J Woolf; Nick A Andrews
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

Review 6.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

Review 7.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

8.  Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Chronic Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Christopher E Forsmark; Dana K Andersen; John T Farrar; Megan Golden; Aida Habtezion; Sohail Z Husain; Liang Li; Julia Mayerle; Stephen J Pandol; Aliye Uc; Zixi Zhu; Dhiraj Yadav
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

9.  Research Design Characteristics of Published Pharmacologic Randomized Clinical Trials for Irritable Bowel Syndrome and Chronic Pelvic Pain Conditions: An ACTTION Systematic Review.

Authors:  Jennifer S Gewandter; Jenna Chaudari; Katarzyna B Iwan; Rachel Kitt; Sawsan As-Sanie; Gloria Bachmann; Quentin Clemens; H Henry Lai; Frank Tu; G Nicholas Verne; Katy Vincent; Ursula Wesselmann; QiQi Zhou; Dennis C Turk; Robert H Dworkin; Shannon M Smith
Journal:  J Pain       Date:  2018-02-02       Impact factor: 5.820

10.  III. Detecting Treatment Effects in Clinical Trials With Different Indices of Pain Intensity Derived From Ecological Momentary Assessment.

Authors:  Stefan Schneider; Doerte U Junghaenel; Masakatsu Ono; Joan E Broderick; Arthur A Stone
Journal:  J Pain       Date:  2020-10-24       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.